Is AMRN or CING more profitable?

Cingulate has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% Cingulate N/A -238.40% -128.67%

Is ZNTL or CING more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Cingulate N/A -238.40% -128.67%

Which has higher earnings & valuation, CRDL or CING?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Cingulate N/A N/A -$22.45M -$3.59 N/A

Is CRDL or CING more profitable?

Cardiol Therapeutics' return on equity of -180.44% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Cingulate N/A -238.40% -128.67%

Do analysts recommend ACB or CING?

Cingulate has a consensus price target of $27.00, suggesting a potential upside of 423.15%. Given Cingulate's higher probable upside, analysts plainly believe Cingulate is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ACB or CING more profitable?

Cingulate has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Aurora Cannabis -32.26% 4.37% 3.45% Cingulate N/A -238.40% -128.67%

Which has preferable valuation and earnings, NMRA or CING?

Cingulate is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A Cingulate N/A N/A -$22.45M -$3.59 N/A

Is NMRA or CING more profitable?

Cingulate's return on equity of -238.40% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -242.28% -131.32% Cingulate N/A -238.40% -128.67%

Cingulate (CING) Competitors

$5.16 +0.05 (+0.98%)

As of 10:57 AM Eastern

Compare

CING vs. AMRN, ZNTL, CRDL, ACB, and NMRA

Should you buy Cingulate stock or one of its competitors? Cingulate's main competitors and comparable companies include Amarin (AMRN), Zentalis Pharmaceuticals (ZNTL), Cardiol Therapeutics (CRDL), Aurora Cannabis (ACB), and Neumora Therapeutics (NMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cingulate compare to Amarin?

Amarin (NASDAQ:AMRN) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Amarin presently has a consensus target price of $13.00, indicating a potential downside of 7.11%. Cingulate has a consensus target price of $27.00, indicating a potential upside of 423.15%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

22.3% of Amarin shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cingulate has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.38	-$38.80M	-$0.99	N/A
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A

Cingulate has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Cingulate	N/A	-238.40%	-128.67%

In the previous week, Amarin had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Amarin and 1 mentions for Cingulate. Cingulate's average media sentiment score of 1.87 beat Amarin's score of 0.96 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Positive
Cingulate	Very Positive

Amarin has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market.

Summary

Cingulate beats Amarin on 9 of the 15 factors compared between the two stocks.

How does Cingulate compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Cingulate has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.33	-$137.06M	-$1.95	N/A
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A

In the previous week, Zentalis Pharmaceuticals had 6 more articles in the media than Cingulate. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 1 mentions for Cingulate. Cingulate's average media sentiment score of 1.87 beat Zentalis Pharmaceuticals' score of 0.80 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Positive
Cingulate	Very Positive

Zentalis Pharmaceuticals' return on equity of -70.18% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Cingulate	N/A	-238.40%	-128.67%

Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market.

Zentalis Pharmaceuticals presently has a consensus price target of $6.75, indicating a potential upside of 115.31%. Cingulate has a consensus price target of $27.00, indicating a potential upside of 423.15%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

41.3% of Cingulate shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Zentalis Pharmaceuticals and Cingulate tied by winning 7 of the 14 factors compared between the two stocks.

How does Cingulate compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cardiol Therapeutics' return on equity of -180.44% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Cingulate	N/A	-238.40%	-128.67%

Cardiol Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market.

Cardiol Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 444.96%. Cingulate has a consensus price target of $27.00, indicating a potential upside of 423.15%. Given Cardiol Therapeutics' higher possible upside, research analysts plainly believe Cardiol Therapeutics is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cardiol Therapeutics had 3 more articles in the media than Cingulate. MarketBeat recorded 4 mentions for Cardiol Therapeutics and 1 mentions for Cingulate. Cingulate's average media sentiment score of 1.87 beat Cardiol Therapeutics' score of 0.70 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Positive
Cingulate	Very Positive

Summary

Cingulate beats Cardiol Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Cingulate compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Aurora Cannabis has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market.

Cingulate has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	1.00	-$88.13M	-$1.41	N/A
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A

In the previous week, Aurora Cannabis had 11 more articles in the media than Cingulate. MarketBeat recorded 12 mentions for Aurora Cannabis and 1 mentions for Cingulate. Cingulate's average media sentiment score of 1.87 beat Aurora Cannabis' score of 0.25 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Cingulate	Very Positive

Cingulate has a consensus price target of $27.00, suggesting a potential upside of 423.15%. Given Cingulate's higher probable upside, analysts plainly believe Cingulate is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cingulate has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Cingulate	N/A	-238.40%	-128.67%

Summary

Aurora Cannabis beats Cingulate on 8 of the 15 factors compared between the two stocks.

How does Cingulate compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Cingulate is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A

Neumora Therapeutics presently has a consensus target price of $6.57, indicating a potential upside of 666.79%. Cingulate has a consensus target price of $27.00, indicating a potential upside of 423.15%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cingulate's return on equity of -238.40% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Cingulate	N/A	-238.40%	-128.67%

Neumora Therapeutics has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market.

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Neumora Therapeutics had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Neumora Therapeutics and 1 mentions for Cingulate. Cingulate's average media sentiment score of 1.87 beat Neumora Therapeutics' score of 0.93 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Neumora Therapeutics	Positive
Cingulate	Very Positive

Summary

Neumora Therapeutics beats Cingulate on 10 of the 14 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CING vs. The Competition

Export

Metric	Cingulate	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$75.04M	$12.52B	$7.21B	$15.01B
Dividend Yield	N/A	2.63%	2.57%	11.71%
P/E Ratio	-1.44	792.18	273.55	25.41
Price / Sales	N/A	950.57	705.75	112.91
Price / Cash	N/A	89.50	77.71	51.48
Price / Book	16.65	10.47	10.45	6.22
Net Income	-$22.45M	$2.83B	$3.49B	$357.96M
7 Day Performance	-0.94%	-1.37%	-0.38%	-0.13%
1 Month Performance	1.39%	0.84%	-0.13%	-3.34%
1 Year Performance	31.32%	4.08%	19.26%	6.59%

Cingulate Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CING Cingulate	3.01 of 5 stars	$5.16 +1.0%	$27.00 +423.2%	+30.7%	$75.04M	N/A	N/A	20	Positive News
AMRN Amarin	1.1471 of 5 stars	$14.25 +4.5%	$13.00 -8.8%	-6.7%	$300.96M	$213.65M	N/A	360
ZNTL Zentalis Pharmaceuticals	3.6177 of 5 stars	$4.03 +1.0%	$6.75 +67.5%	+115.9%	$288.83M	$67.43M	N/A	160	News Coverage Analyst Forecast
CRDL Cardiol Therapeutics	2.8595 of 5 stars	$2.22 +0.9%	$10.00 +350.5%	+71.3%	$257.92M	N/A	N/A	20
ACB Aurora Cannabis	1.0305 of 5 stars	$3.87 -2.0%	N/A	-23.1%	$250.94M	$314.07M	N/A	1,028	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CING) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cingulate (CING) Competitors

CING vs. AMRN, ZNTL, CRDL, ACB, and NMRA

How does Cingulate compare to Amarin?

Summary

How does Cingulate compare to Zentalis Pharmaceuticals?

Summary

How does Cingulate compare to Cardiol Therapeutics?

Summary

How does Cingulate compare to Aurora Cannabis?

Summary

How does Cingulate compare to Neumora Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CING vs. The Competition

Cingulate Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cingulate (CING) Competitors

CING vs. AMRN, ZNTL, CRDL, ACB, and NMRA

How does Cingulate compare to Amarin?

Do analysts prefer AMRN or CING?

Do institutionals & insiders believe in AMRN or CING?

Which has better earnings & valuation, AMRN or CING?

Is AMRN or CING more profitable?

Does the media refer more to AMRN or CING?

Which has more risk & volatility, AMRN or CING?

Summary

How does Cingulate compare to Zentalis Pharmaceuticals?

Which has stronger valuation & earnings, ZNTL or CING?

Does the media favor ZNTL or CING?

Is ZNTL or CING more profitable?

Which has more risk and volatility, ZNTL or CING?

Do analysts prefer ZNTL or CING?

Do institutionals and insiders have more ownership in ZNTL or CING?

Summary

How does Cingulate compare to Cardiol Therapeutics?

Which has higher earnings & valuation, CRDL or CING?

Do institutionals & insiders have more ownership in CRDL or CING?

Is CRDL or CING more profitable?

Which has more volatility & risk, CRDL or CING?

Do analysts recommend CRDL or CING?

Does the media prefer CRDL or CING?

Summary

How does Cingulate compare to Aurora Cannabis?

Which has more risk and volatility, ACB or CING?

Which has preferable valuation & earnings, ACB or CING?

Does the media favor ACB or CING?

Do analysts recommend ACB or CING?

Do institutionals & insiders have more ownership in ACB or CING?

Is ACB or CING more profitable?

Summary

How does Cingulate compare to Neumora Therapeutics?

Which has preferable valuation and earnings, NMRA or CING?

Do analysts prefer NMRA or CING?

Is NMRA or CING more profitable?

Which has more volatility and risk, NMRA or CING?

Do institutionals & insiders believe in NMRA or CING?

Does the media prefer NMRA or CING?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CING vs. The Competition

Cingulate Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools